Ladenburg Thalmann analyst Kevin DeGeeter assumes coverage on Corvus Pharmaceuticals (NASDAQ: CRVS) with a Buy rating and a price target of $32.00.

For an analyst ratings summary and ratings history on Corvus Pharmaceuticals click here. For more ratings news on Corvus Pharmaceuticals click here.

Shares of Corvus Pharmaceuticals closed at $13.31 yesterday.